Loading…
A class of carbonic anhydrase I - selective activators
A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity....
Saved in:
Published in: | Journal of enzyme inhibition and medicinal chemistry 2017-01, Vol.32 (1), p.37-46 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3 |
container_end_page | 46 |
container_issue | 1 |
container_start_page | 37 |
container_title | Journal of enzyme inhibition and medicinal chemistry |
container_volume | 32 |
creator | Licsandru, Erol Tanc, Muhammet Kocsis, Istvan Barboiu, Mihail Supuran, Claudiu T. |
description | A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood. |
doi_str_mv | 10.1080/14756366.2016.1232254 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14756366_2016_1232254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c867c15dab3f42928f04c8b67ce5d006</doaj_id><sourcerecordid>2195235091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</originalsourceid><addsrcrecordid>eNp9kk2P0zAQhiMEYpeFnwCKxAUOKeNv54K2WgFbqRIXOFvO2NmmSuPFTov673FIt2L3wGms8TvPjD1vUbwlsCCg4RPhSkgm5YICkQtCGaWCPysup3wlmeLPz2cpL4pXKW0BKKGEvywuqFK1rpW6LOSyxN6mVIa2RBubMHRY2mFzdNEmX67Kqky-9zh2B1_aKdgxxPS6eNHaPvk3p3hV_Pz65cfNbbX-_m11s1xXqJgcKwUttoJwJpWsGXiLyBEId95x1SjpmAMmRSOVsCDRE_AaCDCCDr1AZFfFaua6YLfmPnY7G48m2M78TYR4Z2wcO-y9QS0VEuFsw1pOa6pb4KgzOpMcgMyszzPrft_sfG4wjNH2j6CPb4ZuY-7Cwcg8EmiSAR9nwOZJ2e1ybaZc3oQimurDpP1wahbDr71Po9l1CX3f28GHfTJEM5H3UXOdpe-fSLdhH4f8rYaSWtAsrCegmFUYQ0rRt-cJCJjJEebBEWZyhDk5Ite9-_fV56oHC2TB9SzohjbEnf0dYu_MaI99iG20A3bJsP_3-AP8_cJv</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2195235091</pqid></control><display><type>article</type><title>A class of carbonic anhydrase I - selective activators</title><source>Taylor & Francis_OA刊</source><source>PubMed Central</source><creator>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</creator><creatorcontrib>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</creatorcontrib><description>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</description><identifier>ISSN: 1475-6366</identifier><identifier>EISSN: 1475-6374</identifier><identifier>DOI: 10.1080/14756366.2016.1232254</identifier><identifier>PMID: 27798977</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Alzheimer's disease ; Anchoring to zinc-coordinated water ; Animals ; Anticonvulsants ; Biological activity ; carbonic anhydrase ; Carbonic anhydrase I ; Carbonic Anhydrase I - chemistry ; Carbonic Anhydrase I - drug effects ; Carbonic Anhydrase I - metabolism ; Chemical Sciences ; Cognitive ability ; Crystallography, X-Ray ; Enzyme Activators - pharmacology ; Histamine ; Humans ; inhibition mechanism ; inhibitors ; Isocyanates ; Neurodegenerative diseases ; occlusion of the active site entrance ; out of the active site binding ; Physiology ; Protein Conformation ; Proton Magnetic Resonance Spectroscopy ; Spectrometry, Mass, Electrospray Ionization</subject><ispartof>Journal of enzyme inhibition and medicinal chemistry, 2017-01, Vol.32 (1), p.37-46</ispartof><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2016</rights><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/Licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2016 The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</citedby><cites>FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</cites><orcidid>0000-0003-0042-9483</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010081/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010081/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27501,27923,27924,53790,53792,59142,59143</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27798977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-01671828$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Licsandru, Erol</creatorcontrib><creatorcontrib>Tanc, Muhammet</creatorcontrib><creatorcontrib>Kocsis, Istvan</creatorcontrib><creatorcontrib>Barboiu, Mihail</creatorcontrib><creatorcontrib>Supuran, Claudiu T.</creatorcontrib><title>A class of carbonic anhydrase I - selective activators</title><title>Journal of enzyme inhibition and medicinal chemistry</title><addtitle>J Enzyme Inhib Med Chem</addtitle><description>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</description><subject>Alzheimer's disease</subject><subject>Anchoring to zinc-coordinated water</subject><subject>Animals</subject><subject>Anticonvulsants</subject><subject>Biological activity</subject><subject>carbonic anhydrase</subject><subject>Carbonic anhydrase I</subject><subject>Carbonic Anhydrase I - chemistry</subject><subject>Carbonic Anhydrase I - drug effects</subject><subject>Carbonic Anhydrase I - metabolism</subject><subject>Chemical Sciences</subject><subject>Cognitive ability</subject><subject>Crystallography, X-Ray</subject><subject>Enzyme Activators - pharmacology</subject><subject>Histamine</subject><subject>Humans</subject><subject>inhibition mechanism</subject><subject>inhibitors</subject><subject>Isocyanates</subject><subject>Neurodegenerative diseases</subject><subject>occlusion of the active site entrance</subject><subject>out of the active site binding</subject><subject>Physiology</subject><subject>Protein Conformation</subject><subject>Proton Magnetic Resonance Spectroscopy</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><issn>1475-6366</issn><issn>1475-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk2P0zAQhiMEYpeFnwCKxAUOKeNv54K2WgFbqRIXOFvO2NmmSuPFTov673FIt2L3wGms8TvPjD1vUbwlsCCg4RPhSkgm5YICkQtCGaWCPysup3wlmeLPz2cpL4pXKW0BKKGEvywuqFK1rpW6LOSyxN6mVIa2RBubMHRY2mFzdNEmX67Kqky-9zh2B1_aKdgxxPS6eNHaPvk3p3hV_Pz65cfNbbX-_m11s1xXqJgcKwUttoJwJpWsGXiLyBEId95x1SjpmAMmRSOVsCDRE_AaCDCCDr1AZFfFaua6YLfmPnY7G48m2M78TYR4Z2wcO-y9QS0VEuFsw1pOa6pb4KgzOpMcgMyszzPrft_sfG4wjNH2j6CPb4ZuY-7Cwcg8EmiSAR9nwOZJ2e1ybaZc3oQimurDpP1wahbDr71Po9l1CX3f28GHfTJEM5H3UXOdpe-fSLdhH4f8rYaSWtAsrCegmFUYQ0rRt-cJCJjJEebBEWZyhDk5Ite9-_fV56oHC2TB9SzohjbEnf0dYu_MaI99iG20A3bJsP_3-AP8_cJv</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Licsandru, Erol</creator><creator>Tanc, Muhammet</creator><creator>Kocsis, Istvan</creator><creator>Barboiu, Mihail</creator><creator>Supuran, Claudiu T.</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Informa Healthcare</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0042-9483</orcidid></search><sort><creationdate>20170101</creationdate><title>A class of carbonic anhydrase I - selective activators</title><author>Licsandru, Erol ; Tanc, Muhammet ; Kocsis, Istvan ; Barboiu, Mihail ; Supuran, Claudiu T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer's disease</topic><topic>Anchoring to zinc-coordinated water</topic><topic>Animals</topic><topic>Anticonvulsants</topic><topic>Biological activity</topic><topic>carbonic anhydrase</topic><topic>Carbonic anhydrase I</topic><topic>Carbonic Anhydrase I - chemistry</topic><topic>Carbonic Anhydrase I - drug effects</topic><topic>Carbonic Anhydrase I - metabolism</topic><topic>Chemical Sciences</topic><topic>Cognitive ability</topic><topic>Crystallography, X-Ray</topic><topic>Enzyme Activators - pharmacology</topic><topic>Histamine</topic><topic>Humans</topic><topic>inhibition mechanism</topic><topic>inhibitors</topic><topic>Isocyanates</topic><topic>Neurodegenerative diseases</topic><topic>occlusion of the active site entrance</topic><topic>out of the active site binding</topic><topic>Physiology</topic><topic>Protein Conformation</topic><topic>Proton Magnetic Resonance Spectroscopy</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Licsandru, Erol</creatorcontrib><creatorcontrib>Tanc, Muhammet</creatorcontrib><creatorcontrib>Kocsis, Istvan</creatorcontrib><creatorcontrib>Barboiu, Mihail</creatorcontrib><creatorcontrib>Supuran, Claudiu T.</creatorcontrib><collection>Taylor & Francis_OA刊</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Licsandru, Erol</au><au>Tanc, Muhammet</au><au>Kocsis, Istvan</au><au>Barboiu, Mihail</au><au>Supuran, Claudiu T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A class of carbonic anhydrase I - selective activators</atitle><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle><addtitle>J Enzyme Inhib Med Chem</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>32</volume><issue>1</issue><spage>37</spage><epage>46</epage><pages>37-46</pages><issn>1475-6366</issn><eissn>1475-6374</eissn><abstract>A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>27798977</pmid><doi>10.1080/14756366.2016.1232254</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0042-9483</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1475-6366 |
ispartof | Journal of enzyme inhibition and medicinal chemistry, 2017-01, Vol.32 (1), p.37-46 |
issn | 1475-6366 1475-6374 |
language | eng |
recordid | cdi_crossref_primary_10_1080_14756366_2016_1232254 |
source | Taylor & Francis_OA刊; PubMed Central |
subjects | Alzheimer's disease Anchoring to zinc-coordinated water Animals Anticonvulsants Biological activity carbonic anhydrase Carbonic anhydrase I Carbonic Anhydrase I - chemistry Carbonic Anhydrase I - drug effects Carbonic Anhydrase I - metabolism Chemical Sciences Cognitive ability Crystallography, X-Ray Enzyme Activators - pharmacology Histamine Humans inhibition mechanism inhibitors Isocyanates Neurodegenerative diseases occlusion of the active site entrance out of the active site binding Physiology Protein Conformation Proton Magnetic Resonance Spectroscopy Spectrometry, Mass, Electrospray Ionization |
title | A class of carbonic anhydrase I - selective activators |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20class%20of%20carbonic%20anhydrase%20I%20-%20selective%20activators&rft.jtitle=Journal%20of%20enzyme%20inhibition%20and%20medicinal%20chemistry&rft.au=Licsandru,%20Erol&rft.date=2017-01-01&rft.volume=32&rft.issue=1&rft.spage=37&rft.epage=46&rft.pages=37-46&rft.issn=1475-6366&rft.eissn=1475-6374&rft_id=info:doi/10.1080/14756366.2016.1232254&rft_dat=%3Cproquest_cross%3E2195235091%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c736t-70fcf5143676930eacc4c014ded47b76d3d0365b675a06ce10e801031cdce5cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2195235091&rft_id=info:pmid/27798977&rfr_iscdi=true |